Pediatric dyslipidemia: Recommendations for clinical management

Southern Medical Journal

Volumn 108, Issue 1, 2015, Pages 7-14

  Wilson, Don P ^a,b,c   McNeal, Catherine ^a,b,c   Blackett, Piers ^a,b,c  

^a Children's Medical Center   (United States)

^b Texas AandM University Health Science Center   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Pediatric dyslipidemia; Risk factors; Treatment guidelines; Youth

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; FIBRIC ACID DERIVATIVE; OMEGA 3 FATTY ACID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; CHILD HEALTH CARE; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; DRUG SAFETY; DYSLIPIDEMIA; GENE MUTATION; HUMAN; LIFESTYLE; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCREENING TEST; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; BLOOD; COMPLICATION; DYSLIPIDEMIAS; MASS SCREENING; PRACTICE GUIDELINE; RISK REDUCTION; STANDARDS; YOUNG ADULT;

ADOLESCENT; ATHEROSCLEROSIS; CHILD; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; TRIGLYCERIDES; YOUNG ADULT;

EID: 84925029032     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.14423/SMJ.0000000000000219     Document Type: Review

References (41)

1. Newman WP 3rd, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986; 314: 138-144.
2. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998; 338: 1650-1656.
3. McGill HC Jr, McMahan CA, Zieske AW, et al. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation 2001; 103: 1546-1550.
4. McGill HC Jr, McMahan CA, Malcolm GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 1997; 17: 95-106.
5. Davis PH, Dawson JD, RileyWA, et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104: 2815-2819.
6. Raitakari OT, Juonala M, Mahoney M, et al. Cardiovascular risk factors in childhood and carotid intima-media thickness in adulthood: The Cardiovascular Risk in Young Finns Study. JAMA 2003; 290: 2277-2283.
7. Urbina EM, Kieltkya L, Tsai J, et al. Impact of multiple cardiovascular risk factors on brachial artery distensibility in young adults: The Bogalusa Heart Study. Am J Hypertens 2005; 18: 767-771.
8. Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation 1998; 98: 2580-2583.
9. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report. Pediatrics 2011; 128(Suppl 5): S213-S256.
10. National Cholesterol Education Program (NCEP): Highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 495-501.
11. Daniels SR, Greer FR. Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.
12. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA 2012; 307: 259-260.
13. Kavey RE, McBride PE. Should family physicians routinely screen for hypercholesterolemia in children? Yes: The evidence supports universal screening. Am Fam Physician 2012; 86: 1-2.
14. LefevreM. Should family physicians routinely screen for hypercholesterolemia in children? No: Universal screening has uncertain benefits and a high risk of harms. Am Fam Physician 2012; 86: 1-2.
15. Preventive US. Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics 2007; 120: E215-e219.
16. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: E21-e181.
17. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood) 2007; 26: 13-24.
18. Magnussen CG, Koskinen J, Chen W, et al. Pediatric metabolic syndrome predicts adulthood metabolic syndrome, subclinical atherosclerosis, and type 2 diabetes mellitus but is no better than body mass index alone: The Bogalusa Heart Study and the Cardiovascular Risk in Young Finns Study. Circulation 2010; 122: 1604-1611.
19. Davis PH, Dawson JD, Riley WA, et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 2001; 104: 2815-2019.
20. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid intima-media thickness in adulthood: The Cardiovascular Risk in Young Finns Study. JAMA 2003; 290: 2277-2283.
21. McNeal CJ, Underland L, Wilson DP, et al. Pediatric lipid screening. Clin Lipidol 2013; 8: 425-436.
22. Olson RE. Atherogenesis in children: Implications for the prevention of atherosclerosis. Adv Pediatr 2000; 47: 55-78.
23. Brunzell JD. Familial lipoprotein lipase deficiency. Gene Rev. www.ncbi. nlm.nih.gov/books/NBK1308. Published 1999. Accessed December 15, 2014.
24. Blackett P, Tryggestad J, Krishnan S, et al. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J Clin Lipidol 2013; 7: 132-139.
25. Wright RS. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol. Curr Opin Cardiol 2013; 28: 389-398.
26. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J 2008; 29: 2625-2633.
27. Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management. Scientific SteeringCommittee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142: 105-112.
28. Rogowski WH, Grosse SD, John J, et al. Points to consider in assessing and appraising predictive genetic tests. J Community Genet 2010; 1: 185-194.
29. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled trial. JAMA 2004; 292: 331-337.
30. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and metaanalysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-1810.
31. Lavigne JV, Brown KM, Gidding S, et al. A cholesterol-lowering diet does not produce adverse psychological effects in children: Three-year results from the dietary intervention study in children. Health Psychol 1999; 18: 604-613.
32. Salo P, Seppänen-Laakso T, Laakso I, et al. Low-saturated fat, lowcholesterol diet in 3-year-old children: Effect on intake and composition of trans fatty acids and other fatty acids in serum phospholipid fractionVThe STRIP study. Special Turku coronary Risk factor Intervention Project for children. J Pediatr 2000; 136: 46-52.
33. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Costeffectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med 2004; 4: 97-104.
34. Marks D, Wonderling D, Thorogood M, et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002; 324: 1303.
35. Smets EM, Stam MM, Meulenkamp TM, et al. Health-related quality of life of children with a positive carrier status for inherited cardiovascular diseases. Am J Med Genet A 2008; 146A: 700-707.
36. Lifshitz F, Tarim O. Considerations about dietary fat restrictions for children. J Nutr 1996; 126(4 suppl): 1031S-1041S.
37. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: Knowledge base, limitations, and future directions. Pediatrics 2007; 119: 370-380.
38. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
39. Ridker PM. What works and in whom? A simple, easily applied, evidencebased approach to guidelines for statin therapy. Circ Cardiovas Qual Outcomes 2012; 5: 592-593.
40. McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97: 89C-94C.
41. Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atheroscler Suppl 2014; 15: 1-15.